Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Exosome Diagnostics, 1Drop Diagnostics, Siemens Healthineers, and More

NEW YORK (GenomeWeb) – The American Medical Association this week issued a new CPT Proprietary Analyses (PLA) code for Exosome Diagnostics' ExoDx Prostate (IntelliScore) test. The new 0005U code becomes effective on May 1 and is specific to Exosome's test. Exosome said that being assigned the new code is a crucial step to expanding commercialization of its test in the US.

Point-of-care instrument maker 1Drop Diagnostics this week announced it has received a $140,000 grant from the Consortia for Improving Medicine with Innovation & Technology and the National Institute for Biomedical Imaging and Bioengineering in order to continue funding the firm's collaboration with Massachusetts General Hospital. The partners are aiming to develop point-of-care diagnostics for heart disease in primary care settings. Additionally, MGH will provide 1Drop with clinical guidance, help identifying unmet clinical needs, and an environment in which to perform validation studies.

Siemens Healthineers this week announced that it has installed India’s first fully automated Aptio Automation track with multidisciplinary modalities at the Aspira Pathlab and Diagnostic Limited in Mumbai. The firm noted that the new track will enable Aspira to perform all routine hematology, biochemistry, and immunoassay tests with a comprehensive selection of pre- and post-analytical modules that automate sample loading, preparation, and handling.

Theradiag reported this week that its first quarter revenues grew 5 percent year over year to €2.3 million ($2.5 million) from €2.2 million a year ago. In vitro diagnostics revenues were down 15 percent to €1.1 million from €1.3 million a year ago, while revenues associated with the firm's theranostics solution, Lisa Tracker, rose 22 percent to €1.1 million from €903,000 a year ago. International sales came in at €1.2 million, accounting for half of the firm's total revenues, it said.

Congenica said this week that it has completed a Series B funding round with additional investments from new investors BGI, Healthlink Capital, and Future Planet Capital. The company did not specify the amount of the funding. BGI and UniteGen, Healthlink's clinical diagnostic lab, have signed commercial contracts to use Congenica's enterprise software, Sapientia, to support their operations in China.

MilliporeSigma announced this week that it will sponsor the Startup Program at a biotechnology incubator called LabCentral in Cambridge, Massachusetts. MilliporeSigma’s collaboration with LabCentral gives biotech startups access to process development tools, education programs, and training. As a sponsor of the LabCentral Startup Program, MilliporeSigma will adopt a startup company, which entitles the selected company to a priority spot and one-year prepaid lab bench in LabCentral’s shared workspace. Candidates can submit their application at until July 2.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.